Works by Uchida, Shunya


Results: 77
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Favorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function.

    Published in:
    Therapeutic Apheresis & Dialysis, 2022, v. 26, n. 1, p. 220, doi. 10.1111/1744-9987.13694
    By:
    • Muso, Eri;
    • Sakai, Soichi;
    • Ogura, Youske;
    • Yukawa, Susumu;
    • Nishizawa, Yoshiki;
    • Yorioka, Noriaki;
    • Saito, Takao;
    • Mune, Masatoshi;
    • Sugiyama, Satoshi;
    • Iino, Yasuhiko;
    • Hirano, Tsutomu;
    • Hattori, Motoshi;
    • Watanabe, Tsuyoshi;
    • Yokoyama, Hitoshi;
    • Sato, Hiroshi;
    • Uchida, Shunya;
    • Wada, Takashi;
    • Shoji, Tetsuo;
    • Oda, Hiroaki;
    • Mori, Kiyoshi
    Publication type:
    Article
    11
    12

    SLC23A3 is a renal hypoxanthine transporter.

    Published in:
    Nucleosides, Nucleotides & Nucleic Acids, 2022, v. 41, n. 12, p. 1279, doi. 10.1080/15257770.2022.2028826
    By:
    • Hosoyamada, Makoto;
    • Tomioka, Naoko H.;
    • Watanabe, Tamaki;
    • Yasuno, Nobuhiro;
    • Uchida, Shunya;
    • Shibata, Shigeru
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20

    The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

    Published in:
    Trials, 2014, v. 15, n. 1, p. 1, doi. 10.1186/1745-6215-15-26
    By:
    • Tatsuo Hosoya;
    • Kenjiro Kimura;
    • Sadayoshi Itoh;
    • Masaaki Inaba;
    • Shunya Uchida;
    • Yasuhiko Tomino;
    • Hirofumi Makino;
    • Seiichi Matsuo;
    • Tetsuya Yamamoto;
    • Iwao Ohno;
    • Yugo Shibagaki;
    • Satoshi Iimuro;
    • Naohiko Imai;
    • Masanari Kuwabara;
    • Hiroshi Hayakawa
    Publication type:
    Article
    21

    The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.

    Published in:
    2014
    By:
    • Hosoya, Tatsuo;
    • Kimura, Kenjiro;
    • Itoh, Sadayoshi;
    • Inaba, Masaaki;
    • Uchida, Shunya;
    • Tomino, Yasuhiko;
    • Makino, Hirofumi;
    • Matsuo, Seiichi;
    • Yamamoto, Tetsuya;
    • Ohno, Iwao;
    • Shibagaki, Yugo;
    • Iimuro, Satoshi;
    • Imai, Naohiko;
    • Kuwabara, Masanari;
    • Hayakawa, Hiroshi
    Publication type:
    journal article
    22
    23
    24
    25
    26
    27

    Incidence and factors associated with prescribing renin‐angiotensin‐system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study.

    Published in:
    Journal of Clinical Hypertension, 2021, v. 23, n. 5, p. 999, doi. 10.1111/jch.14224
    By:
    • Nishiwaki, Hiroki;
    • Niihata, Kakuya;
    • Shimizu, Sayaka;
    • Shibagaki, Yugo;
    • Yamamoto, Ryohei;
    • Nitta, Kosaku;
    • Tsukamoto, Tatsuo;
    • Uchida, Shunya;
    • Takeda, Asami;
    • Okada, Hirokazu;
    • Narita, Ichiei;
    • Isaka, Yoshitaka;
    • Kurita, Noriaki;
    • Imai, Enyu;
    • Maruyama, Shoichi;
    • Sato, Toshinobu;
    • Sato, Hiroshi;
    • Wada, Takashi;
    • Hayashi, Hiroki;
    • Akai, Yasuhiro
    Publication type:
    Article
    28
    29

    Effects of the N/L-Type Calcium Channel Blocker Cilnidipine on Nephropathy and Uric Acid Metabolism in Hypertensive Patients With Chronic Kidney Disease (J- CIRCLE Study).

    Published in:
    Journal of Clinical Hypertension, 2014, v. 16, n. 10, p. 746, doi. 10.1111/jch.12412
    By:
    • Uchida, Shunya;
    • Takahashi, Masato;
    • Sugawara, Masahiro;
    • Saito, Tomoaki;
    • Nakai, Kazuhiko;
    • Fujita, Masami;
    • Mochizuki, Koichi;
    • Shin, Isu;
    • Morita, Takashi;
    • Hikita, Tomoyuki;
    • Itakura, Hironao;
    • Takahashi, Yuko;
    • Mizuno, Shigeki;
    • Ohno, Yasumi;
    • Ito, Kageki;
    • Ito, Takafumi;
    • Soma, Masayoshi
    Publication type:
    Article
    30

    Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial.

    Published in:
    Clinical & Experimental Nephrology, 2023, v. 27, n. 9, p. 757, doi. 10.1007/s10157-023-02362-w
    By:
    • Maruyama, Shoichi;
    • Kurasawa, Shimon;
    • Hayashi, Terumasa;
    • Nangaku, Masaomi;
    • Narita, Ichiei;
    • Hirakata, Hideki;
    • Tanabe, Kenichiro;
    • Morita, Satoshi;
    • Tsubakihara, Yoshiharu;
    • Imai, Enyu;
    • Akizawa, Tadao;
    • PREDICT Investigators;
    • Hiramatsu, Takeyuki;
    • Tamai, Hirofumi;
    • Iida, Yoshiyasu;
    • Naruse, Tomohiro;
    • Oishi, Hideto;
    • Uchida, Shunya;
    • Shimizu, Hideaki;
    • Morozumi, Kunio
    Publication type:
    Article
    31

    Initiation of renin–angiotensin system inhibitors and first complete remission in patients with primary nephrotic syndrome: a nationwide cohort study.

    Published in:
    Clinical & Experimental Nephrology, 2023, v. 27, n. 5, p. 480, doi. 10.1007/s10157-023-02331-3
    By:
    • Shimizu, Sayaka;
    • Niihata, Kakuya;
    • Nishiwaki, Hiroki;
    • Shibagaki, Yugo;
    • Yamamoto, Ryohei;
    • Nitta, Kosaku;
    • Tsukamoto, Tatsuo;
    • Uchida, Shunya;
    • Takeda, Asami;
    • Okada, Hirokazu;
    • Narita, Ichiei;
    • Isaka, Yoshitaka;
    • Kurita, Noriaki;
    • Nishio, Saori;
    • Ishikawa, Yasunobu;
    • Nakazawa, Daigo;
    • Nakagaki, Tasuku;
    • Sato, Toshinobu;
    • Sato, Mitsuhiro;
    • Sanada, Satoru
    Publication type:
    Article
    32

    Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS).

    Published in:
    Clinical & Experimental Nephrology, 2022, v. 26, n. 12, p. 1170, doi. 10.1007/s10157-022-02256-3
    By:
    • Kimura, Tomonori;
    • Yamamoto, Ryohei;
    • Yoshino, Mitsuaki;
    • Sakate, Ryuichi;
    • Imai, Enyu;
    • Maruyama, Shoichi;
    • Yokoyama, Hitoshi;
    • Sugiyama, Hitoshi;
    • Nitta, Kosaku;
    • Tsukamoto, Tatsuo;
    • Uchida, Shunya;
    • Takeda, Asami;
    • Sato, Toshinobu;
    • Wada, Takashi;
    • Hayashi, Hiroki;
    • Akai, Yasuhiro;
    • Fukunaga, Megumu;
    • Tsuruya, Kazuhiko;
    • Masutani, Kosuke;
    • Konta, Tsuneo
    Publication type:
    Article
    33

    Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS).

    Published in:
    Clinical & Experimental Nephrology, 2020, v. 24, n. 10, p. 893, doi. 10.1007/s10157-020-01913-9
    By:
    • Yokoyama, Hitoshi;
    • Yamamoto, Ryohei;
    • Imai, Enyu;
    • Maruyama, Shoichi;
    • Sugiyama, Hitoshi;
    • Nitta, Kosaku;
    • Tsukamoto, Tatsuo;
    • Uchida, Shunya;
    • Takeda, Asami;
    • Sato, Toshinobu;
    • Wada, Takashi;
    • Hayashi, Hiroki;
    • Akai, Yasuhiro;
    • Fukunaga, Megumu;
    • Tsuruya, Kazuhiko;
    • Masutani, Kosuke;
    • Konta, Tsuneo;
    • Shoji, Tatsuya;
    • Hiramatsu, Takeyuki;
    • Goto, Shunsuke
    Publication type:
    Article
    34

    Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS).

    Published in:
    Clinical & Experimental Nephrology, 2020, v. 24, n. 6, p. 526, doi. 10.1007/s10157-020-01864-1
    By:
    • Yamamoto, Ryohei;
    • Imai, Enyu;
    • Maruyama, Shoichi;
    • Yokoyama, Hitoshi;
    • Sugiyama, Hitoshi;
    • Nitta, Kosaku;
    • Tsukamoto, Tatsuo;
    • Uchida, Shunya;
    • Takeda, Asami;
    • Sato, Toshinobu;
    • Wada, Takashi;
    • Hayashi, Hiroki;
    • Akai, Yasuhiro;
    • Fukunaga, Megumu;
    • Tsuruya, Kazuhiko;
    • Masutani, Kosuke;
    • Konta, Tsuneo;
    • Shoji, Tatsuya;
    • Hiramatsu, Takeyuki;
    • Goto, Shunsuke
    Publication type:
    Article
    35

    Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study.

    Published in:
    Clinical & Experimental Nephrology, 2018, v. 22, n. 6, p. 1266, doi. 10.1007/s10157-018-1579-x
    By:
    • Yamamoto, Ryohei;
    • Imai, Enyu;
    • Maruyama, Shoichi;
    • Yokoyama, Hitoshi;
    • Sugiyama, Hitoshi;
    • Nitta, Kosaku;
    • Tsukamoto, Tatsuo;
    • Uchida, Shunya;
    • Takeda, Asami;
    • Sato, Toshinobu;
    • Wada, Takashi;
    • Hayashi, Hiroki;
    • Akai, Yasuhiro;
    • Fukunaga, Megumu;
    • Tsuruya, Kazuhiko;
    • Masutani, Kosuke;
    • Konta, Tsuneo;
    • Shoji, Tatsuya;
    • Hiramatsu, Takeyuki;
    • Goto, Shunsuke
    Publication type:
    Article
    36

    Time to target uric acid to retard CKD progression.

    Published in:
    Clinical & Experimental Nephrology, 2017, v. 21, n. 2, p. 182, doi. 10.1007/s10157-016-1288-2
    By:
    • Kumagai, Takanori;
    • Ota, Tatsuru;
    • Tamura, Yoshifuru;
    • Chang, Wen;
    • Shibata, Shigeru;
    • Uchida, Shunya
    Publication type:
    Article
    37
    38
    39
    40

    Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.

    Published in:
    Clinical & Experimental Nephrology, 2015, v. 19, n. 3, p. 465, doi. 10.1007/s10157-014-1017-7
    By:
    • Kato, Hideki;
    • Shiraishi, Takeshi;
    • Ueda, Shuko;
    • Kubo, Eiji;
    • Shima, Tomoko;
    • Nagura, Michito;
    • Yano, Hirofumi;
    • Izumikawa, Yuh;
    • Shimada, Masaru;
    • Tomioka, Satoru;
    • Nosaka, Hitonari;
    • Kojima, Kenichiro;
    • Tanemoto, Masayuki;
    • Uchida, Shunya
    Publication type:
    Article
    41

    Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.

    Published in:
    Clinical & Experimental Nephrology, 2015, v. 19, n. 3, p. 379, doi. 10.1007/s10157-014-0996-8
    By:
    • Muso, Eri;
    • Mune, Masatoshi;
    • Hirano, Tsutomu;
    • Hattori, Motoshi;
    • Kimura, Kenjiro;
    • Watanabe, Tsuyoshi;
    • Yokoyama, Hitoshi;
    • Sato, Hiroshi;
    • Uchida, Shunya;
    • Wada, Takashi;
    • Shoji, Tetsuo;
    • Yuzawa, Yukio;
    • Takemura, Tsukasa;
    • Sugiyama, Satoshi;
    • Nishizawa, Yoshiki;
    • Ogahara, Satoru;
    • Yorioka, Noriaki;
    • Sakai, Soichi;
    • Ogura, Yosuke;
    • Yukawa, Susumu
    Publication type:
    Article
    42
    43
    44
    45
    46
    47

    Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study

    Published in:
    Clinical & Experimental Nephrology, 2003, v. 7, n. 3, p. 221, doi. 10.1007/s10157-003-0241-3
    By:
    • Iino, Yasuhiko;
    • Hayashi, Matsuhiko;
    • Kawamura, Tetsuya;
    • Shiigai, Tatsuo;
    • Tomino, Yasuhiko;
    • Yamada, Kenichi;
    • Kitajima, Takeyuki;
    • Ideura, Terukuni;
    • Koyama, Akio;
    • Sugisaki, Tetsuzo;
    • Suzuki, Hiromichi;
    • Umemura, Satoshi;
    • Kawaguchi, Yoshindo;
    • Uchida, Shunya;
    • Kuwahara, Michio;
    • Yamazaki, Tsutomu
    Publication type:
    Article
    48
    49
    50